A recently published meta-analysis suggested that high levels of intratumoral and interstitial CD8+ T cells can predict the efficacy of immunotherapy in multiple tumor types, including immunotherapy alone and immunocombination therapy (Li et al., 2021). This evidence concerns the gene CD8A and neoplasm.